银杏叶提取物治疗慢性肺源性心脏病40例临床观察  

Clinical observation of the ginkgo biloba extract on the treatment of 40 cases with chronic pulmonary heart disease

作　　者：谭玉萍[1] 彭绍杰[1] 康善平[1] 梁炜[1] 

机构地区：[1]广西中医学院附属瑞康医院干部病房,南宁530011

出　　处：《中国实用医药》2008年第25期21-22,共2页China Practical Medicine

摘　　要：目的观察银杏叶提取物辅助治疗慢性肺源性心脏病(简称肺心病)急性加重期的疗效及治疗前后血浆C反应蛋白、纤维蛋白原、D-二聚体含量的变化。方法观察40例肺心病急性加重期患者在常规治疗基础上,加用银杏提取物20ml加入5%葡萄糖注射液(或生理盐水)中静脉滴注,1次/d,14d为1个疗程。另38例以常规治疗为对照组。结果两组显效率分别为87.50%和68.42%,总有效率为97.50%和86.84%,差异有统计学意义(P<0.05);治疗后两组间血浆C反应蛋白含量差异有统计学意义(P<0.01),纤维蛋白原、D-二聚体含量差异有有统计学意义(P<0.05)。结论银杏叶提取物可明显改善机体炎症反应,降低血黏度,提高肺心病急性加重期的临床疗效。Objective To observe the curative effect of ginkgo biloba extract on the treatment of chronic pulmonary heart disease at the acute exacerbation stage, and the changes of plasma C reactive protein,fibrinogeM and D-dimer between pre and post treatment. Methods The ginkgo biloba extract 20 ml/d were given by intravenous drip for 14 days as a course of treatment based on the routine treatment in 40 cases with chronic pulmonary heart disease at acute exacerbation stage ,which were dissolved into 5% glucose injection or 0. 9% sodium chloride injection.. The other 38 cases with routine treatment served as control group. Results The obvious effective rate and total effective rate of the treatment group were 87.50% and 97.50%. The control group were 68.42% and 86. 84%. There were significant differences between the 2 groups （P 〈 0. 01 ）. To compare the level of plasma C reactive protein after treatment between 2 groups, the difference was highly significant（ P 〈 0. 01 ）. To compare the level of the plasma fibrinogen and D-dimer after treatment, there were significant differences between the 2 groups （ P 〈 0. 05 ）. Conclusion The ginkgo biloba extract could obviously decrease systemic inflammatory response, reduce blood viscosity and improve the clinical efficacy on chronic pulmonary heart disease at the acute exacerbation stage.

关 键 词：慢性肺源性心脏病 银杏叶提取物 治疗 

分 类 号：R259[医药卫生—中西医结合]